One Solution, a clear path to the clinic.
BMD-1141 is our patent-protected lead asset, a first-in-class hair-cycle stimulator with a development strategy designed to generate clinical signal efficiently.
Lead asset
BMD-1141
A patented collagen-binding-domain / parathyroid-hormone (PTH–CBD) molecule. Extensive in-vivo efficacy has been demonstrated in alopecia areata and chemotherapy-induced alopecia models, with strong scientific rationale to address multiple causes of alopecia.
- Lead market: androgenetic alopecia, a signal of clinical effect would address a 30B+ opportunity.
- Additional clinical focus: alopecia areata, an effective non-immunosuppressant option with a known FDA pathway.
- Strong preclinical safety,highly favorable safety in preclinical studies to date.
A capital-efficient route to human proof-of-concept.
Discovery is complete. The plan advances BMD-1141 through IND-enabling work and into early clinical study, designed to read out a signal of efficacy.
01
Complete
Discovery
Proof-of-concept efficacy in key animal models; toxicology including MTD, repeat-dose and PK/PD; manufacturing platform and formulations developed.
02
Next
IND-Enabling
GMP manufacturing of bulk drug substance, IND-enabling GLP toxicology, and regulatory preparation toward an IND application.
03
Future
First-in-Human
A randomized, single-ascending-dose, placebo-controlled study in a population enriched for androgenetic alopecia, monitoring for a signal of efficacy.
Target product profile
Precision Medicine
For Better
Outcomes.
The profile we’re building toward is differentiated on every axis that matters to patients and prescribers, convenience, durability, and a clean tolerability story relative to today’s options.
Intellectual property
Protected across the board.
19
Patents granted & filed
Composition of matter
- Fusion construct
- Novel linkage
- Functional sequence variants
- Receptor targeting
Methods & field of use
- Alopecia & hair growth
- Bone disorders
- Soft-tissue regeneration
Formulation & delivery
- Topical & transdermal
- Injectable depot
- Targeted delivery devices
Mechanism & PK
- Extended tissue half-life
- Reduced systemic clearance
A first-in-class regenerative therapy for androgenetic alopecia and other forms of hair loss — building quality of life.
© 2026 Flourish Biologics
This website is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any securities. Forward-looking statements regarding the company’s research and development are subject to risks and uncertainties.